Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 327, pseudogene (RNU6-327P) is a pseudogene derived from the sequence of the U6 small nuclear RNA gene family. Pseudogenes are generally non-coding genomic DNA sequences that resemble normal genes but are typically nonfunctional due to mutations or absence of necessary regulatory sequences[1][4][6]. The canonical U6 small nuclear RNA (U6 snRNA) is an essential component of the spliceosome, the cellular machinery that splices precursor messenger RNA (pre-mRNA) in eukaryotic nuclei[7][3][5]. However, RNU6-327P itself does not encode a functional small nuclear RNA and is not known to participate in splicing or other cellular processes[1][4]. There is no evidence indicating that RNU6-327P serves as a protein, receptor, or drug target, nor is it known to be implicated in disease, act as a biomarker, or interact with any drugs. The presence of RNU6-327P represents genomic redundancy and evolutionary byproducts associated with the high copy number and conservation of U6 snRNA genes in the human genome[7][1][4]. Further details: - Is_incorrect flag justification: RNU6-327P is *not* a functional gene or protein, *not a therapeutic target*, and pseudogenes of this class do not have established direct roles or known druggability according to curated genetic resources[1][4]. The canonical U6 snRNA is essential, but this entry is a pseudogene. - Distinction: This record refers *only* to a nonfunctional pseudogene and not the U6 snRNA itself, which is critical for splicing but is also not considered a typical therapeutic drug target[3][5][7]. No evidence was found that RNU6-327P has a role in disease, interacts with drugs, or serves as a biomarker. This designation matches conventions for pseudogenes and non-target sequences[1][4][6].
Not applicable (not a druggable target)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 327, pseudogene (RNU6-327P).